Leading Strategies for Antibody Discovery Against Difficult Targets – Genetic Immunization and Berkeley Lights Beacon®

Leading Strategies for Antibody Discovery Against Difficult Targets – Genetic Immunization and Berkeley Lights Beacon®

Tuesday, March 30, 2021 2:40 PM to 3:00 PM · 20 min. (Africa/Abidjan)

Antibodies

mAbs

Presentation

Information

Genetic immunization – a powerful tool for generating therapeutic antibodies
Combining two powerful technologies, genetic immunization and Berkley Lights’ Beacon®, enables antibody discovery against the most challenging targets
Fully human antibodies blocking new Cov-2 variants are rapidly generated leveraging three advanced platforms: genetic immunization, Beacon® and Ligand’s OmniRat®

Patricia Odermatt, Research Scientist, Genovac

Genovac Antibody DiscoveryGenovac Antibody Discovery delivers advanced antibody discovery solutions for the most difficult targets. The company's immunization technologies, combined with two single B cell platforms and highly efficient hybridoma technology, provides robust delivery of antibodies for therapeutic, diagnostic and R&D applications. As an approved contract research partner of the leading transgenic animal providers, Genovac can rapidly develop human antibodies against the most challenging targets such as GPCRs and ion channels

Log in

See all the content and easy-to-use features by logging in